Position in MYGN
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$1,529,559
+$374,473 QoQ
Shares Held
339,902
+81.0% QoQ
Ownership
0.360%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $12,036,211 across 17 Diagnostics & Research names. MYGN ranks #3 (12.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DHR |
Danaher Corp /De/
|
13,542 | $2,567,563 | |
| 2 | IDXX |
Idexx Laboratories Inc /De
|
2,801 | $1,573,853 | |
| 3 | MYGN |
Myriad Genetics Inc
This page
|
339,902 | $1,529,559 | |
| 4 | A |
Agilent Technologies, Inc.
|
8,721 | $994,019 | |
| 5 | XGN |
Exagen Inc.
|
253,005 | $759,015 | |
| 6 | OPK |
Opko Health, Inc.
|
663,704 | $756,622 | |
| 7 | BDSX |
Biodesix Inc
|
39,406 | $571,387 | |
| 8 | PSNL |
Personalis, Inc.
|
82,175 | $523,454 |
All Filings in MYGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,529,559 | 339,902 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $1,155,086 | 187,819 | Shares | Sole | 2026-02-06 | |
| 2025-06-30 | $59,551 | 11,215 | Shares | Sole | 2025-07-22 | |
| 2024-12-31 | $359,695 | 26,236 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $504,523 | 18,420 | Shares | Sole | 2024-11-05 | |
| 2020-03-31 | $271,847 | 18,997 | Shares | Sole | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||